Table 1 Demographic, clinical, and physical examination data of patients (n = 43)

Age (years)^a

50.4 (8.8)

  < 60 years (n/%)^b

35 (81,4)

  ≥ 60 years (n/%)^b

8 (18.6)

BMI (kg/m²)^a

28.6 (4.8)

  < 25 kg/m² (n/%)^b

7 (16.3)

  ≥ 25 kg/m² (n/%)^b

36 (83.4)

BSA (m²)^a

1.70 (0.14)

HTN (n/%)^b

13 (30.2)

DM (n/%)^b

6 (14.0)

DLP (n/%)^b

6 (14.0)

Smoking (n/%)^b

5 (11.6)

 Right

22 (51.2)

 Left

20 (46.5)

 Bilateral

1 (2.3)

 IDC

40 (93.0)

 ILC

3 (97.0)

HER2+ (n/%)^b

22 (51.2)

 IIa

15 (34.9)

 IIb

12 (27.9)

 IIIa

8 (18.6)

 IIIb

3 (7.0)

 IV

5 (11.6)

Total dose of doxorubicin (mg/m²)^a

248.4 (30.9)

  < 250 mg/m² (n/%)^b

40 (93.0)

  ≥ 250 mg/m² (n/%)^b

3 (7.0)

Trastuzumab (n/%)^b

18 (41.9)